User login
Key clinical point: A once-daily dose of 300 mg aspirin in the adjuvant setting did not reduce risk for breast cancer (BC) recurrence or improve survival outcomes as compared with placebo in patients with high-risk nonmetastatic BC.
Major finding: Treatment with aspirin and placebo led to comparable invasive disease-free survival (hazard ratio [HR] 1.27; P = .06) and overall survival outcomes (HR 1.19; P = .36) along with similar rates of grades 3 and 4 adverse events.
Study details: This phase 3 trial included 3020 patients with high-risk nonmetastatic BC (age 18 to <70 years) and a history of human epidermal growth factor receptor 2-negative BC who were treated with standard therapy and were randomly assigned to receive 300 mg aspirin or placebo once daily.
Disclosures: This study was supported by the US Department of Defense Breast Cancer Research Program and other sources. Five authors declared receiving grants, royalties, or consulting fees from various sources.
Source: Chen WY, Ballman KV, Partridge AH, et al. Aspirin vs placebo as adjuvant therapy for breast cancer: The Alliance A011502 randomized trial. JAMA. 2024 (Apr 29). doi: 10.1001/jama.2024.4840 Source
Key clinical point: A once-daily dose of 300 mg aspirin in the adjuvant setting did not reduce risk for breast cancer (BC) recurrence or improve survival outcomes as compared with placebo in patients with high-risk nonmetastatic BC.
Major finding: Treatment with aspirin and placebo led to comparable invasive disease-free survival (hazard ratio [HR] 1.27; P = .06) and overall survival outcomes (HR 1.19; P = .36) along with similar rates of grades 3 and 4 adverse events.
Study details: This phase 3 trial included 3020 patients with high-risk nonmetastatic BC (age 18 to <70 years) and a history of human epidermal growth factor receptor 2-negative BC who were treated with standard therapy and were randomly assigned to receive 300 mg aspirin or placebo once daily.
Disclosures: This study was supported by the US Department of Defense Breast Cancer Research Program and other sources. Five authors declared receiving grants, royalties, or consulting fees from various sources.
Source: Chen WY, Ballman KV, Partridge AH, et al. Aspirin vs placebo as adjuvant therapy for breast cancer: The Alliance A011502 randomized trial. JAMA. 2024 (Apr 29). doi: 10.1001/jama.2024.4840 Source
Key clinical point: A once-daily dose of 300 mg aspirin in the adjuvant setting did not reduce risk for breast cancer (BC) recurrence or improve survival outcomes as compared with placebo in patients with high-risk nonmetastatic BC.
Major finding: Treatment with aspirin and placebo led to comparable invasive disease-free survival (hazard ratio [HR] 1.27; P = .06) and overall survival outcomes (HR 1.19; P = .36) along with similar rates of grades 3 and 4 adverse events.
Study details: This phase 3 trial included 3020 patients with high-risk nonmetastatic BC (age 18 to <70 years) and a history of human epidermal growth factor receptor 2-negative BC who were treated with standard therapy and were randomly assigned to receive 300 mg aspirin or placebo once daily.
Disclosures: This study was supported by the US Department of Defense Breast Cancer Research Program and other sources. Five authors declared receiving grants, royalties, or consulting fees from various sources.
Source: Chen WY, Ballman KV, Partridge AH, et al. Aspirin vs placebo as adjuvant therapy for breast cancer: The Alliance A011502 randomized trial. JAMA. 2024 (Apr 29). doi: 10.1001/jama.2024.4840 Source